INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 250 participants.

Also called NCT06965504

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 250 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06965504
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06965504. Allocation not applicable; no masking; primary purpose treatment. Start 2026-10-02 (actual); primary completion 2028-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
Acronym
INTeGRATE
Condition
Heart Failure
Condition
Cardiogenic Shock
Condition
Reduced Ejection Fraction Heart Failure
Intervention (Device)
Impella 5.5 SmartAssist
Lead sponsor
Abiomed Inc. (class: industry)
Collaborator
Johnson & Johnson (class: industry)

Record details

Record id
cardio:ct-nct06965504
Content hash
c421629109befaf1fccdf0caa41339bc6a2e8709bb559282135ab17aee882bcc